Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
94,401,153
-
Total 13F shares
-
107,709,232
-
Share change
-
+3,151,817
-
Total reported value
-
$4,486,288,734
-
Put/Call ratio
-
20%
-
Price per share
-
$41.65
-
Number of holders
-
225
-
Value change
-
+$149,976,766
-
Number of buys
-
124
-
Number of sells
-
107
Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q3 2025
As of 30 Sep 2025,
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) was held by
225 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
107,709,232 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Inc., Driehaus Capital Management LLC, FARALLON CAPITAL MANAGEMENT LLC, PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, JANUS HENDERSON GROUP PLC, and Paradigm Biocapital Advisors LP.
This page lists
225
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.